Evidence map›Paper›PMID 30237505›Full record

Trial reportNutrition & diabetes2018

Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial.

Simona Bo, Roberto Gambino, Valentina Ponzo, Iolanda Cioffi, Ilaria Goitre, Andrea Evangelista, Giovannino Ciccone, Maurizio Cassader, Massimo Procopio

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrition & diabetes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 8 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 8 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Resveratrol for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020
    Pooled it
  8. Pooled it
  9. Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo-Controlled Trial.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020
    Trial
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Simona BoDepartment of Medical Sciences, University of Turin, Turin, Italy. simona.bo@unito.it.
Roberto GambinoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Valentina PonzoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Iolanda CioffiDepartment of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.
Ilaria GoitreDepartment of Medical Sciences, University of Turin, Turin, Italy.
Andrea EvangelistaUnit of Clinical Epidemiology, CPO, "Città della Salute e della Scienza" Hospital of Turin, Turin, Italy.
Giovannino CicconeUnit of Clinical Epidemiology, CPO, "Città della Salute e della Scienza" Hospital of Turin, Turin, Italy.
Maurizio CassaderDepartment of Medical Sciences, University of Turin, Turin, Italy.
Massimo ProcopioDepartment of Medical Sciences, University of Turin, Turin, Italy.
University of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITFederico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPatients with type 2 diabetes (T2DM) are at increased fracture risk. Resveratrol has shown beneficial effects on bone health in few studies. The aim of this trial was to investigate the effects of resveratrol on bone mineral density (BMD) and on calcium metabolism biomarkers in T2DM patients.

methodsIn this double-blind randomized placebo-controlled trial 192 T2DM outpatients were randomized to receive resveratrol 500 mg/day (Resv500 arm), resveratrol 40 mg/day (Resv40 arm) or placebo for 6 months. BMD, bone mineral content (BMC), serum calcium, phosphorus, alkaline phosphatase, and 25-hydroxy vitamin D were measured at baseline and after 6 months.

resultsAt follow-up, calcium concentrations increased in all patients, while within-group variations in alkaline phosphatase were higher in both resveratrol arms, and 25-hydroxy vitamin D increased in the Resv500 arm only, without between-group differences. Whole-body BMD significantly decreased in the placebo group, while whole-body BMC decreased in both the placebo and Resv40 arms. No significant changes in BMD and BMC values occurred in the Resv500 arm. The adjusted mean differences of change from baseline were significantly different in the Resv500 arm vs placebo for whole-body BMD (0.01 vs -0.03 g/cm

conclusionsSupplementation with 500 mg resveratrol prevented bone density loss in patients with T2DM, in particular, in those with unfavorable conditions at baseline.

Indexed as

Absorptiometry, PhotonAgedAlkaline PhosphataseBiomarkersBone DensityCalciumDiabetes Mellitus, Type 2Double-Blind MethodFemaleHumansMaleMiddle AgedPhosphorusResveratrolVitamin D25-hydroxyvitamin DAlkaline PhosphataseBiomarkersCalciumPhosphorusResveratrolVitamin D

Identifiers

PMID30237505
PMCPMC6147949
OpenAlexW2889641643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.